BioMotiv is the for‑profit therapeutic accelerator associated with The Harrington Project for Discovery & Development, a $250 million national initiative centered at University Hospitals in Cleveland. The company leverages an experienced team and advisory board to identify, select, fund, and actively manage a portfolio of physician‑scientist–derived programs sourced from research institutions and disease foundations. Its model focuses on advancing bench discoveries through proof of concept and into clinical development with the goal of eventual commercialization. As part of a new strategic partnership, Takeda has made an initial 25 oku‑yen ($25M USD) investment in BioMotiv payable over five years and obtained exclusive rights to programs BioMotiv sources in Immunology & Inflammation and cardio‑metabolic diseases. BioMotiv says the partnership is intended to provide a seamless continuum of expertise to accelerate development of physician‑scientist innovations. The arrangement links BioMotiv’s accelerator model with Takeda’s pharmaceutical capabilities to push prioritized programs toward clinical development and commercialization. BioMotiv is a Cleveland, OK-based for-profit therapeutic accelerator affiliated with The Harrington Project for Discovery and Development. Led by CEO Baiju R. Shah, the company sources a technology portfolio from leading academic medical centers and industry sources across the country. The company intends to use its recent funding to launch operations and initiate development of that portfolio. BioMotiv raised $21M from founding investors University Hospitals and the Harrington Family. The Harrington Project is a $250M initiative announced by University Hospitals in February. BioMotiv plans to raise a total of $100M in capital.

Total raised

$44M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2014